相关实验视频

Updated: May 5, 2026

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

导航悖论:成功地同时植入心脏收缩度调制装置和微型无心脏起器

Gabriele Pavani^1,2,3,4, Paolo Garrone^1,3, Gianpaolo Varalda^1,3

¹Cardiac Electrophysiology Unit, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy.

Journal of cardiovascular electrophysiology

|January 10, 2026

概括

这项研究提出了一种新的双设备策略,用于管理心脏衰竭患者的心脏粉症 (ATTRwt-CA). 同时植入心脏收缩性调制 (CCM) 和Micra无心脏起器,为"悖论"提供了可行的解决方案.

科学领域:

心脏病学心脏病学
医疗器械医疗器械
心脏衰竭管理的管理

背景情况:

野生类型的心脏粉症 (ATTRwt-CA) 经常导致耐火性心力衰竭.
这是一个很棒的节目,这是一个很棒的节目.
这就是悖论.
描述了使用Micra无心脏起器的患者需要随后进行基于的心脏收缩性调制 (CCM) 治疗的情况.

研究的目的:

描述第一个心脏收缩度调制 (CCM) 和Micra无心脏起器设备的共同植入.
评估这种双设备策略在患有ATTRwt-CA和晚期心力衰竭的患者中的可行性和安全性.

主要方法:

一名78岁的男性患有ATTRwt-CA和NYHA III心力衰竭,同时接受了CCM和Micra设备的植入.
采用多视图光学,以确保设备之间的空间分离足够.
实施了特定的编程协议,以减轻潜在的电气交叉通话.

主要成果:

患者的临床稳定性得到证实,在1年的随访期内,从NYHA Class III改善到Class II心力衰竭.
在随访期间,没有进一步的心力衰竭住院记录.
同植入手术在技术上是成功的,并且耐受性很好.

结论:

结合CCM和Micra设备的植入是一种可行和安全的技术方法,用于管理ATTRwt-CA的复杂心力衰竭患者.
这一战略有效地应对了全球经济所带来的挑战.
这就是悖论.
在这个患者群体中.

关键词:

调节心脏收缩率的心脏收缩率调节心脏氨基粉症的发生.案例报告案例报告设备设备的交互电生理学技术技术电生理学技术无心脏起器是一种无心脏起器.

更多相关视频

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

相关概念视频

Mitral Regurgitation III: Medical Management

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...

Mitral Stenosis III: Medical Management

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...